骨髓纤维化的生物学与当代管理
骨髓纤维化是一种发病机制复杂的骨髓增殖性肿瘤,JAK2、CALR或MPL驱动突变见于90%患者,介导组成性JAK-STAT信号,并与表观遗传改变共同参与发病。异常未成熟巨核细胞分泌多种细胞因子和生长因子,导致骨髓纤维化和骨硬化。预后评估工具MIPSS 70-plus version 2.0和GIPSS整合遗传学信息,指导风险适配治疗,但缺乏疾病修饰药物,异基因移植可使部分患者获得长期缓解。
要点
- JAK2、CALR或MPL驱动突变见于90%骨髓纤维化患者,介导组成性JAK-STAT信号。
- 异常巨核细胞低表达GATA1并分泌IL-1β、TGF-β等因子,促进纤维化和骨硬化。
- 预后评估采用整合细胞遗传学和分子信息的MIPSS 70-plus version 2.0和GIPSS评分系统。
核心结论
- 骨髓纤维化发病涉及JAK-STAT信号、表观遗传改变和异常巨核细胞分泌的细胞因子网络。
- 预后评估工具MIPSS 70-plus version 2.0和GIPSS整合遗传学信息,是风险适配治疗决策的核心。
- 疾病修饰药物缺乏是主要挑战,异基因移植可使部分患者获得长期缓解。
研究设计与样本
- 综述,总结骨髓纤维化发病机制和新兴管理策略。
主要发现
- JAK2、CALR或MPL驱动突变见于90%患者,介导组成性JAK-STAT信号。
- 表观遗传改变涉及ASXL1、DNMT3A、SRSF2、EZH2、IDH1/2突变。
- 异常未成熟巨核细胞GATA1蛋白表达降低,分泌IL-1β、TGF-β、b-FGF、PDGF、VEGF及纤连蛋白、层粘连蛋白、胶原等。
- 巨核细胞、成骨细胞、内皮细胞、基质细胞和肌成纤维细胞间相互作用 disrupted,导致纤维化和骨硬化。
关键数值与推荐
- MIPSS 70-plus version 2.0和GIPSS预后评分系统整合细胞遗传学和分子信息。
- 驱动突变JAK2、CALR或MPL见于90%骨髓纤维化患者。
临床怎么用
- 采用MIPSS 70-plus version 2.0或GIPSS进行预后分层,指导风险适配治疗。
- 对部分患者考虑异基因移植以争取长期缓解。
局限性
- 疾病修饰药物缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. Driver mutations involving JAK2, CALR or MPL in 90% of patients mediate constitutive JAK-STAT signaling which, in concert with epigenetic alterations (ASXL1, DNMT3A, SRSF2, EZH2, IDH1/2 mutations), play a fundamental role in disease pathogenesis. Aberrant immature megakaryocytes are a quintessential feature, exhibiting reduced GATA1 protein expression and secreting a plethora of pro-inflammatory cytokines (IL-1 ß, TGF-ß), growth factors (b-FGF, PDGF, VEGF) in addition to extra cellular matrix components (fibronectin, laminin, collagens). The ensuing disrupted interactions amongst the megakaryocytes, osteoblasts, endothelium, stromal cells and myofibroblasts within the bone marrow culminate in the development of fibrosis and osteosclerosis. Presently, prognostic assessment tools for primary myelofibrosis (PMF) are centered on genetics, with incorporation of cytogenetic and molecular information into the mutation-enhanced (MIPSS 70-plus version 2.0) and genetically-inspired (GIPSS) prognostic scoring systems. Both models illustrate substantial clinical heterogeneity in PMF and serve as the crux for risk-adapted therapeutic decisions. A major challenge remains the dearth of disease-modifying drugs, whereas allogeneic transplant offers the chance of long-term remission for some patients. Our review serves to synopsise current appreciation of the pathogenesis of myelofibrosis together with emerging management strategies.
引用
- Gangat N, Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol. 2020. PMID: 32196650. doi:10.1111/bjh.16576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。